|
ENT1 and ENT2 Functional Knockout HeLa Cell Lines
This invention operates by utilizing equilibrative nucleoside transporter (ENT) proteins for the study of cellular processes and other varieties of pharmacological research. Researchers at the University of Arizona have developed ENT1 and ENT2 functional knockout cell lines that lack the ability to transport nucleosides normally, which can be useful...
Published: 11/6/2024
|
Inventor(s): Nathan Cherrington, Siennah Miller Greenfield
Keywords(s):
Category(s): Technology Classifications > Research Tools > Cell Lines
|
|
EZE-Gluc to Identify At-Risk Patients
This technology is a functional test to assess which patients will have toxicity to drugs that use the same transporters as ezetimibe glucuronide, or EZE-Gluc. By administering ezetimibe, a commonly used drug, as a predictive diagnostic tool, healthcare providers can gauge the likelihood of treatment success for various medications. The key lies in...
Published: 7/25/2024
|
Inventor(s): Nathan Cherrington
Keywords(s):
Category(s): Technology Classifications > Healthcare Portfolios > Diabetes, Metabolism, Endocrinology & Obesity, Technology Classifications > Life Sciences > Diagnostics, Technology Classifications > Medical Devices > Diagnostic
|
|
Elisa Test for EZE-Gluc (EZE-MASH)
This innovation is an ELISA assay test designed to help identify patients with Metabolic Dysfunction-Associated Steatohepatitis (MASH) by measuring levels of ezetimibe glucuronide, or EZE-Gluc, in urine. EZE-Gluc is a byproduct of the drug ezetimibe, which is processed differently in people with MASH, resulting in higher levels of EZE-Gluc in their...
Published: 7/25/2024
|
Inventor(s): Nathan Cherrington
Keywords(s):
Category(s): Technology Classifications > Healthcare Portfolios > Diabetes, Metabolism, Endocrinology & Obesity, Technology Classifications > Life Sciences > Diagnostics, Technology Classifications > Medical Devices > Diagnostic
|
|
Drug Metabolite as a Non-Invasive Biomarker for Nonalcoholic Steatohepatitis (NASH)
This invention is a novel approach to diagnosing patients with Non-Alcoholic Steatohepatitis (NASH). Typically NASH is diagnosed through invasive liver biopsies. This technology evades the traditional risks associated with liver biopsies in favor of a diagnosis that incorporates a pill and collection of corresponding blood or urine analysis to determine...
Published: 11/16/2023
|
Inventor(s): Nathan Cherrington
Keywords(s):
Category(s): Technology Classifications > Healthcare Portfolios, Technology Classifications > Life Sciences > Biomarkers
|
